Evidence map›Paper›PMID 39438320›Full record

ArticleAnnals of hematology2024

Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience.

Benjamin J Lee, Shawn P Griffin, Jean Doh, Stefan O Ciurea, Deepa Jeyakumar, Piyanuch Kongtim, Kiran Naqvi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Benjamin J LeeDepartment of Pharmacy, Chao Family Comprehensive Cancer Center, University of California Irvine Health, 101 The City Drive South, Bldg. 23, Rm 275, Orange, CA, 92868, USA. benjaml9@hs.uci.edu.ORCID https://orcid.org/0000-0002-1678-1345
Shawn P GriffinDepartment of Pharmacy, Chao Family Comprehensive Cancer Center, University of California Irvine Health, 101 The City Drive South, Bldg. 23, Rm 275, Orange, CA, 92868, USA.ORCID https://orcid.org/0000-0002-3818-2490
Jean DohDepartment of Pharmacy, Chao Family Comprehensive Cancer Center, University of California Irvine Health, 101 The City Drive South, Bldg. 23, Rm 275, Orange, CA, 92868, USA.ORCID https://orcid.org/0000-0003-2737-5243
Stefan O CiureaDepartment of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, CA, USA.ORCID https://orcid.org/0000-0001-8597-3271
Deepa JeyakumarDepartment of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, CA, USA.ORCID https://orcid.org/0000-0002-8822-1814
Piyanuch KongtimDepartment of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, CA, USA.ORCID https://orcid.org/0000-0003-2130-7645
Kiran NaqviDepartment of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, CA, USA.ORCID https://orcid.org/0000-0002-5511-6153

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
NCI NIH HHS P30 CA062203
6 · The paper itself

Abstract

Outcomes for patients with myeloid blast phase chronic myeloid leukemia (CML-MBP) are dismal, and no preferred chemotherapy regimen has been identified. Recent studies have suggested a higher response rate with administration of timed-sequenced regimens (TSR) (purine analog, high-dose cytarabine, anthracycline) in high-risk acute myeloid leukemia patients. We retrospectively evaluated outcomes of newly diagnosed CML-MBP patients consecutively treated at our institution with a TSR or standard-dose cytarabine and an anthracycline ("7 + 3") combined with a tyrosine-kinase inhibitor (TKI) between 2011 and 2023. Endpoints of interest included hematologic response, clinically significant cytogenetic response (CSCR) defined as achieving at least a minor cytogenetic response (Ph + metaphases 0%-≤65%) after induction therapy, event-free survival (EFS), and overall survival (OS). A total of 18 patients with CML-MBP were included of whom 9 (50%) received a TSR and 9 (50%) received "7 + 3". Hematologic response (55.6% vs. 55.6%) and CSCR (25% vs. 37.5%) were similar between TSR- and "7 + 3" treated patients. Twelve patients (66.7%) experienced at least one grade ≥ 3 non-hematologic, end-organ toxicity with 33.3% and 11.1% of TSR- and 7 + 3-treated patients, respectively, experiencing at least two. Our data suggests that intensification of upfront chemotherapy does not appear to improve treatment outcomes in CML-MBP patients however, further studies are warranted to confirm these findings involving a larger cohort.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBlast CrisisCytarabineLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAdultAgedAnthracyclinesDisease-Free SurvivalFemaleHumansMaleMiddle AgedProtein Kinase InhibitorsRetrospective StudiesSurvival RateTreatment OutcomeAnthracyclinesCytarabineProtein Kinase Inhibitors“7 + 3” chemotherapyBlast-phase CMLChronic myeloid leukemiaMyeloid blast crisisTyrosine kinase inhibitor

Identifiers

PMID39438320
PMCPMC11695490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.